HyperMed Imaging, Inc. Secures New Financing
January 1, 2014 / Greenwich, CT
HyperMed Imaging, Inc. has closed its first installment of private Series B financing with existing and new investors. Use of proceeds will include the development, testing, clinical trials and regulatory clearance activities for the company’s new medical imaging device for tissue oximetry. The company recently completed advanced research resulting in new intellectual property that will enable its next generation of product based on the company’s core technology in medical hyperspectral imaging.
HyperMed Imaging, Inc. is a privately owned medical device company and the market leader in hyperspectral medical imaging. HyperMed pioneered the use of its novel version of hyperspectral imaging for assessment of surface tissue oximetry with its OxyVu™-1 device, first cleared by the FDA in 2006. HyperMed’s OxyVu-1 has been successfully used across America for many years, generating substantial clinical research for use of the technology in a number of applications involving circulatory compromise. HyperMed is not currently selling any medical device and is focusing its efforts toward a new generation of devices using its hyperspectral imaging technology.